Here, Paolo Ghia, MD, PhD, of Vita-Salute San Raffaele University in Milan, Italy, discusses recent findings from the phase II CAPTIVATE study evaluating fixed-duration first-line treatment with ibrutinib plus venetoclax in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.